Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment

A Systematic Review

Roderick C. N. van den Bergh, Niels J. van Casteren, Thomas van den Broeck, Eve R. Fordyce, William K. M. Gietzmann, Fiona Stewart, Steven MacLennan, Saeed Dabestani, Joaquim Bellmunt, Michel Bolla, Erik Briers, Philip Cornford, Steven Joniau, Malcolm D. Mason, Vsevolod Matveev, Henk G. van der Poel, Theo H. van der Kwast, Olivier Rouvière, Thomas Wiegel, Thomas B. Lam & 1 others Nicolas Mottet*

*Corresponding author for this work

Research output: Contribution to journalArticle

30 Citations (Scopus)
7 Downloads (Pure)

Abstract

Context: The relative benefits and harms of hormonal treatment (HT) versus no or deferred HT in patients with nonmetastatic prostate cancer (PCa) relapse after primary curative therapy are controversial. Objective: To assess the effectiveness of HT for nonmetastatic PCa relapse, prognostic factors for treatment outcome, timing of treatment, and the most effective treatment strategy to provide guidance for clinical practice. Evidence acquisition: A systematic literature search was undertaken incorporating Medline, Embase, and the Cochrane Library (search ended March 2015). Studies were critically appraised for risk of bias. The outcomes included overall and cancer-specific survival, metastasis-free survival, symptom-free survival, progression to castrate resistance, adverse events, and quality of life. Evidence synthesis: Of 9687 articles identified, 27 studies were eligible for inclusion (2 RCTs, 8 nonrandomised comparative studies, and 17 case series). The results suggest that only a subgroup of patients, especially those with high-risk disease, may benefit from early HT. The main predictors for unfavourable outcomes were shorter PSA doubling time (<6–12 mo) and higher Gleason score (>7). Early HT may be warranted for patients with high-risk disease. An intermittent HT strategy appears feasible. Most studies had a moderate to high risks of bias. Conclusions: HT for PCa relapse after primary therapy with curative intent should be reserved for patients at highest risk of progression and with a long life expectancy. The potential benefits of starting HT should be judiciously balanced against the associated harms. Patient summary: This article summarises the evidence on the benefits and harms of hormonal treatment in prostate cancer (PCa) patients in whom the disease has recurred following earlier curative treatment. We found that only a select group of patients with aggressive PCa and a fast rising prostate-specific antigen may benefit from early hormonal treatment (HT), whereas in others HT may be more harmful than beneficial.
Original languageEnglish
Pages (from-to)802-820
Number of pages19
JournalEuropean Urology
Volume69
Issue number5
Early online date12 Dec 2015
DOIs
Publication statusPublished - May 2016

Fingerprint

Prostatic Neoplasms
Recurrence
Therapeutics
Prostate-Specific Antigen
Life Expectancy
Libraries
Disease-Free Survival
Quality of Life
Neoplasm Metastasis

Keywords

  • Curative treatment
  • EAU
  • Guidelines
  • Hormonal
  • Non-metastatic
  • Prostate cancer
  • Recurrence
  • Systematic review
  • Therapy

ASJC Scopus subject areas

  • Urology

Cite this

van den Bergh, R. C. N., van Casteren, N. J., van den Broeck, T., Fordyce, E. R., Gietzmann, W. K. M., Stewart, F., ... Mottet, N. (2016). Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. European Urology, 69(5), 802-820. https://doi.org/10.1016/j.eururo.2015.11.023

Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment : A Systematic Review. / van den Bergh, Roderick C. N.; van Casteren, Niels J.; van den Broeck, Thomas; Fordyce, Eve R.; Gietzmann, William K. M.; Stewart, Fiona; MacLennan, Steven; Dabestani, Saeed; Bellmunt, Joaquim; Bolla, Michel; Briers, Erik; Cornford, Philip; Joniau, Steven; Mason, Malcolm D.; Matveev, Vsevolod; van der Poel, Henk G.; van der Kwast, Theo H.; Rouvière, Olivier; Wiegel, Thomas; Lam, Thomas B.; Mottet, Nicolas.

In: European Urology, Vol. 69, No. 5, 05.2016, p. 802-820.

Research output: Contribution to journalArticle

van den Bergh, RCN, van Casteren, NJ, van den Broeck, T, Fordyce, ER, Gietzmann, WKM, Stewart, F, MacLennan, S, Dabestani, S, Bellmunt, J, Bolla, M, Briers, E, Cornford, P, Joniau, S, Mason, MD, Matveev, V, van der Poel, HG, van der Kwast, TH, Rouvière, O, Wiegel, T, Lam, TB & Mottet, N 2016, 'Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review', European Urology, vol. 69, no. 5, pp. 802-820. https://doi.org/10.1016/j.eururo.2015.11.023
van den Bergh, Roderick C. N. ; van Casteren, Niels J. ; van den Broeck, Thomas ; Fordyce, Eve R. ; Gietzmann, William K. M. ; Stewart, Fiona ; MacLennan, Steven ; Dabestani, Saeed ; Bellmunt, Joaquim ; Bolla, Michel ; Briers, Erik ; Cornford, Philip ; Joniau, Steven ; Mason, Malcolm D. ; Matveev, Vsevolod ; van der Poel, Henk G. ; van der Kwast, Theo H. ; Rouvière, Olivier ; Wiegel, Thomas ; Lam, Thomas B. ; Mottet, Nicolas. / Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment : A Systematic Review. In: European Urology. 2016 ; Vol. 69, No. 5. pp. 802-820.
@article{504469537f194543addc0b3baab2bac3,
title = "Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review",
abstract = "Context: The relative benefits and harms of hormonal treatment (HT) versus no or deferred HT in patients with nonmetastatic prostate cancer (PCa) relapse after primary curative therapy are controversial. Objective: To assess the effectiveness of HT for nonmetastatic PCa relapse, prognostic factors for treatment outcome, timing of treatment, and the most effective treatment strategy to provide guidance for clinical practice. Evidence acquisition: A systematic literature search was undertaken incorporating Medline, Embase, and the Cochrane Library (search ended March 2015). Studies were critically appraised for risk of bias. The outcomes included overall and cancer-specific survival, metastasis-free survival, symptom-free survival, progression to castrate resistance, adverse events, and quality of life. Evidence synthesis: Of 9687 articles identified, 27 studies were eligible for inclusion (2 RCTs, 8 nonrandomised comparative studies, and 17 case series). The results suggest that only a subgroup of patients, especially those with high-risk disease, may benefit from early HT. The main predictors for unfavourable outcomes were shorter PSA doubling time (<6–12 mo) and higher Gleason score (>7). Early HT may be warranted for patients with high-risk disease. An intermittent HT strategy appears feasible. Most studies had a moderate to high risks of bias. Conclusions: HT for PCa relapse after primary therapy with curative intent should be reserved for patients at highest risk of progression and with a long life expectancy. The potential benefits of starting HT should be judiciously balanced against the associated harms. Patient summary: This article summarises the evidence on the benefits and harms of hormonal treatment in prostate cancer (PCa) patients in whom the disease has recurred following earlier curative treatment. We found that only a select group of patients with aggressive PCa and a fast rising prostate-specific antigen may benefit from early hormonal treatment (HT), whereas in others HT may be more harmful than beneficial.",
keywords = "Curative treatment, EAU, Guidelines, Hormonal, Non-metastatic, Prostate cancer, Recurrence, Systematic review, Therapy",
author = "{van den Bergh}, {Roderick C. N.} and {van Casteren}, {Niels J.} and {van den Broeck}, Thomas and Fordyce, {Eve R.} and Gietzmann, {William K. M.} and Fiona Stewart and Steven MacLennan and Saeed Dabestani and Joaquim Bellmunt and Michel Bolla and Erik Briers and Philip Cornford and Steven Joniau and Mason, {Malcolm D.} and Vsevolod Matveev and {van der Poel}, {Henk G.} and {van der Kwast}, {Theo H.} and Olivier Rouvi{\`e}re and Thomas Wiegel and Lam, {Thomas B.} and Nicolas Mottet",
note = "Funding/Support and role of the sponsor: None. Acknowledgments: This systematic review (and meta-analysis) was performed under the auspices of the European Association of Urology Guidelines Office Board and the European Association of Urology Prostate Cancer Guidelines Panel.",
year = "2016",
month = "5",
doi = "10.1016/j.eururo.2015.11.023",
language = "English",
volume = "69",
pages = "802--820",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment

T2 - A Systematic Review

AU - van den Bergh, Roderick C. N.

AU - van Casteren, Niels J.

AU - van den Broeck, Thomas

AU - Fordyce, Eve R.

AU - Gietzmann, William K. M.

AU - Stewart, Fiona

AU - MacLennan, Steven

AU - Dabestani, Saeed

AU - Bellmunt, Joaquim

AU - Bolla, Michel

AU - Briers, Erik

AU - Cornford, Philip

AU - Joniau, Steven

AU - Mason, Malcolm D.

AU - Matveev, Vsevolod

AU - van der Poel, Henk G.

AU - van der Kwast, Theo H.

AU - Rouvière, Olivier

AU - Wiegel, Thomas

AU - Lam, Thomas B.

AU - Mottet, Nicolas

N1 - Funding/Support and role of the sponsor: None. Acknowledgments: This systematic review (and meta-analysis) was performed under the auspices of the European Association of Urology Guidelines Office Board and the European Association of Urology Prostate Cancer Guidelines Panel.

PY - 2016/5

Y1 - 2016/5

N2 - Context: The relative benefits and harms of hormonal treatment (HT) versus no or deferred HT in patients with nonmetastatic prostate cancer (PCa) relapse after primary curative therapy are controversial. Objective: To assess the effectiveness of HT for nonmetastatic PCa relapse, prognostic factors for treatment outcome, timing of treatment, and the most effective treatment strategy to provide guidance for clinical practice. Evidence acquisition: A systematic literature search was undertaken incorporating Medline, Embase, and the Cochrane Library (search ended March 2015). Studies were critically appraised for risk of bias. The outcomes included overall and cancer-specific survival, metastasis-free survival, symptom-free survival, progression to castrate resistance, adverse events, and quality of life. Evidence synthesis: Of 9687 articles identified, 27 studies were eligible for inclusion (2 RCTs, 8 nonrandomised comparative studies, and 17 case series). The results suggest that only a subgroup of patients, especially those with high-risk disease, may benefit from early HT. The main predictors for unfavourable outcomes were shorter PSA doubling time (<6–12 mo) and higher Gleason score (>7). Early HT may be warranted for patients with high-risk disease. An intermittent HT strategy appears feasible. Most studies had a moderate to high risks of bias. Conclusions: HT for PCa relapse after primary therapy with curative intent should be reserved for patients at highest risk of progression and with a long life expectancy. The potential benefits of starting HT should be judiciously balanced against the associated harms. Patient summary: This article summarises the evidence on the benefits and harms of hormonal treatment in prostate cancer (PCa) patients in whom the disease has recurred following earlier curative treatment. We found that only a select group of patients with aggressive PCa and a fast rising prostate-specific antigen may benefit from early hormonal treatment (HT), whereas in others HT may be more harmful than beneficial.

AB - Context: The relative benefits and harms of hormonal treatment (HT) versus no or deferred HT in patients with nonmetastatic prostate cancer (PCa) relapse after primary curative therapy are controversial. Objective: To assess the effectiveness of HT for nonmetastatic PCa relapse, prognostic factors for treatment outcome, timing of treatment, and the most effective treatment strategy to provide guidance for clinical practice. Evidence acquisition: A systematic literature search was undertaken incorporating Medline, Embase, and the Cochrane Library (search ended March 2015). Studies were critically appraised for risk of bias. The outcomes included overall and cancer-specific survival, metastasis-free survival, symptom-free survival, progression to castrate resistance, adverse events, and quality of life. Evidence synthesis: Of 9687 articles identified, 27 studies were eligible for inclusion (2 RCTs, 8 nonrandomised comparative studies, and 17 case series). The results suggest that only a subgroup of patients, especially those with high-risk disease, may benefit from early HT. The main predictors for unfavourable outcomes were shorter PSA doubling time (<6–12 mo) and higher Gleason score (>7). Early HT may be warranted for patients with high-risk disease. An intermittent HT strategy appears feasible. Most studies had a moderate to high risks of bias. Conclusions: HT for PCa relapse after primary therapy with curative intent should be reserved for patients at highest risk of progression and with a long life expectancy. The potential benefits of starting HT should be judiciously balanced against the associated harms. Patient summary: This article summarises the evidence on the benefits and harms of hormonal treatment in prostate cancer (PCa) patients in whom the disease has recurred following earlier curative treatment. We found that only a select group of patients with aggressive PCa and a fast rising prostate-specific antigen may benefit from early hormonal treatment (HT), whereas in others HT may be more harmful than beneficial.

KW - Curative treatment

KW - EAU

KW - Guidelines

KW - Hormonal

KW - Non-metastatic

KW - Prostate cancer

KW - Recurrence

KW - Systematic review

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84949654377&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2015.11.023

DO - 10.1016/j.eururo.2015.11.023

M3 - Article

VL - 69

SP - 802

EP - 820

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -